503 related articles for article (PubMed ID: 33836637)
21. Impact of rapid sequential combination therapy on distinct haemodynamic measures in newly diagnosed pulmonary arterial hypertension.
Kramer T; Nattmann P; Gerhardt F; Stafiej P; Dumitrescu D; Ten Freyhaus H; Wißmüller M; Hohmann C; Baldus S; Rosenkranz S
ESC Heart Fail; 2024 Jun; 11(3):1540-1552. PubMed ID: 38224960
[TBL] [Abstract][Full Text] [Related]
22. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
[TBL] [Abstract][Full Text] [Related]
23. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2019; 122-123():106599. PubMed ID: 31629919
[TBL] [Abstract][Full Text] [Related]
24. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
D'Alto M; Badagliacca R; Lo Giudice F; Argiento P; Casu G; Corda M; Correale M; Ghio S; Greco A; Lattanzio M; Mercurio V; Paciocco G; Papa S; Prediletto R; Romeo E; Russo MG; Tayar A; Vitulo P; Vizza CD; Golino P; Naeije R
J Heart Lung Transplant; 2020 Dec; 39(12):1389-1397. PubMed ID: 32933828
[TBL] [Abstract][Full Text] [Related]
25. Modulating NO-GC Pathway in Pulmonary Arterial Hypertension.
D'Agostino A; Lanzafame LG; Buono L; Crisci G; D'Assante R; Leone I; De Vito L; Bossone E; Cittadini A; Marra AM
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203205
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
[No Abstract] [Full Text] [Related]
27. Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Bowles EA; Moody GN; Yeragunta Y; Stephenson AH; Ellsworth ML; Sprague RS
Exp Biol Med (Maywood); 2015 Jan; 240(1):121-7. PubMed ID: 25125498
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
White RJ; Vonk-Noordegraaf A; Rosenkranz S; Oudiz RJ; McLaughlin VV; Hoeper MM; Grünig E; Ghofrani HA; Chakinala MM; Barberà JA; Blair C; Langley J; Frost AE
Respir Res; 2019 Sep; 20(1):208. PubMed ID: 31511080
[TBL] [Abstract][Full Text] [Related]
29. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Price LC; Howard LS
Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
[TBL] [Abstract][Full Text] [Related]
30. Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.
Nakamura K; Akagi S; Ejiri K; Yoshida M; Miyoshi T; Toh N; Nakagawa K; Takaya Y; Matsubara H; Ito H
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771203
[TBL] [Abstract][Full Text] [Related]
31. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension.
Zeng C; Liu J; Zheng X; Hu X; He Y
Respir Res; 2023 Nov; 24(1):263. PubMed ID: 37915044
[TBL] [Abstract][Full Text] [Related]
32. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.
Beghetti M; Gorenflo M; Ivy DD; Moledina S; Bonnet D
Pediatr Pulmonol; 2019 Oct; 54(10):1516-1526. PubMed ID: 31313530
[TBL] [Abstract][Full Text] [Related]
33. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
34. Pathways in pulmonary arterial hypertension: the future is here.
Sitbon O; Morrell N
Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
[TBL] [Abstract][Full Text] [Related]
37. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
38. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.
Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Holmes JH; Minhas J; Mazurek JA; Palevsky HI; Ventetuolo CE; Kawut SM
Eur Heart J; 2024 Jun; 45(21):1937-1952. PubMed ID: 38416633
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies in pulmonary arterial hypertension.
Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
